Flatiron Health, an independent affiliate of the Roche Group, announced today that 14 abstracts utilizing its real-world oncology data have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The research demonstrates how AI-driven methodologies and longitudinal data from over five million cancer patients are generating actionable evidence to improve cancer care and clinical research.
"AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution," said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence at Flatiron Health. "Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer."
Breakthrough Research in Breast Cancer and Prostate Cancer
Among the notable presentations is a groundbreaking study that utilized advanced machine learning models to identify a cohort of over 195,000 patients, making it the largest real-world study to date examining circulating tumor DNA (ctDNA) testing in early-stage breast cancer. This research could significantly impact how liquid biopsies are integrated into breast cancer care pathways.
Another important abstract addresses health equity by assessing disparities in the use of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer in the United States. This research highlights Flatiron's commitment to identifying and addressing racial and ethnic disparities in cancer care.
Improving Clinical Trial Access and Efficiency
Flatiron will also present research demonstrating the potential of centralized, tech-enabled screening services to make clinical trial enrollment more efficient, particularly in community oncology settings. This approach shows promise for increasing participation of racially and ethnically underrepresented populations in clinical trials, as demonstrated in a study focusing on multiple myeloma patients.
Leveraging AI for Real-World Evidence
Several abstracts showcase how Flatiron is using machine learning and AI to transform real-world data into actionable insights. One study examines the concordance between response-based clinical trial endpoints and machine learning-generated real-world endpoints, potentially validating new approaches to measuring treatment effectiveness outside of traditional clinical trials.
"Our research portfolio at ASCO 2025 reflects our commitment to using data for good," explained Reisinger. "By applying advanced analytics to real-world data, we're generating evidence that can directly impact clinical decision-making and improve outcomes for cancer patients."
Addressing Social Determinants of Health
The impact of social determinants of health on cancer outcomes is another focus area, with research examining how these factors affect mortality in diffuse large B-cell lymphoma (DLBCL). This study, conducted in partnership with multiple academic institutions including Yale School of Medicine and the University of Colorado at Anschutz, highlights the importance of considering social and economic factors in cancer care.
Diverse Research Portfolio
The complete set of 14 abstracts spans multiple cancer types and research questions, including:
- Racial and ethnic differences in biomarker testing for HR+ HER2- metastatic breast cancer
- Real-world patient characteristics and treatment patterns in metastatic hormone-sensitive prostate cancer
- Surgical and treatment patterns after neoadjuvant checkpoint inhibition in stage II/III non-small cell lung cancer
- Real-world progression-free survival data for CDK4/6 inhibitors plus aromatase inhibitors in HR+/HER2- metastatic breast cancer
- Unmet needs in adults and young patients with B-cell acute lymphoblastic leukemia following second relapse
Looking Forward
Flatiron Health's research at ASCO 2025 aligns with the conference theme, "Driving Knowledge to Action: Building a Better Future," by demonstrating how real-world data can be leveraged to improve cancer care and research. The company continues to expand its capabilities in using data to power smarter care for every person with cancer.
As a healthtech company focused on oncology, Flatiron Health is using machine learning, AI, and real-world evidence to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. The research being presented at ASCO 2025 represents significant progress toward this mission.
